EUVIMEDEUVIMED entdecken
Crossref

Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study

Hee-Young Yoon, Hoseob Kim, Yoonjong Bae, Jin Woo Song iD

European Respiratory Journal · 2025

DOI: 10.1183/13993003.01484-2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Hee-Young Yoon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Respiratory Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pyridones, Idiopathic Pulmonary Fibrosis, Lung Neoplasms, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Idiopathic pulmonary fibrosis (IPF) carries a high risk of lung cancer, but the effect of pirfenidone on lung cancer development remains uncertain. We investigated the association between pirfenidone use and lung cancer development in patients with IPF.

Methods

We included 9938 patients with IPF from the Korean national claims database. Propensity score analysis with inverse probability of treatment weighting (IPTW) and landmark analyses were employed to evaluate lung cancer occurrence according to pirfenidone use. The association was evaluated using Cox regression models adjusted for clinical and socioeconomic variables. A single-centre IPF clinical cohort (n=941) was used for validating the findings.

Results

The mean patient age was 69.4 years, 73.7% were men and 32.1% received pirfenidone. Lung cancer developed in 766 patients with IPF (7.7%; 21.9 cases per 1000 person-years) during a median follow-up of 3.0 years. After IPTW, the pirfenidone group showed lower incidence (10.4 versus 27.9 cases per 1000 person-years) than the no pirfenidone group. Landmark analysis at 6 months after IPF diagnosis also showed lower incidence of lung cancer in the pirfenidone group than in the no pirfenidone group. Pirfenidone use was independently associated with a reduced lung cancer risk (weighted adjusted hazard ratio (HR) 0.347, 95% CI 0.258–0.466). A clinical cohort showed similar association (weighted adjusted HR 0.716, 95% CI 0.517–0.991). The association persisted across subgroups defined by age or sex.

Conclusion

Pirfenidone use may be associated with a reduced lung cancer risk in patients with IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesIdiopathic Pulmonary FibrosisLung NeoplasmsAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleAgedMiddle AgedIncidenceRepublic of KoreaProportional Hazards ModelsRisk FactorsPropensity ScoreDatabases, Factual

Substanzen

pirfenidonePyridonesAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Division of Allergy and Respiratory Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Data Science, Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.
  • Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea jwsongasan@gmail.com.

ORCID-Profile: Jin Woo Song

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Yoon, H. Y., Kim, H., Bae, Y., & Song, J. W. (2025). Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. European Respiratory Journal. https://doi.org/10.1183/13993003.01484-2024

Vancouver

Yoon HY, Kim H, Bae Y, Song JW. Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. European Respiratory Journal. 2025. doi:10.1183/13993003.01484-2024

BibTeX
@article{Yoon2025,
  author = {Yoon, Hee-Young and Kim, Hoseob and Bae, Yoonjong and Song, Jin Woo},
  title = {Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.01484-2024}
}
Kostenlos starten →